Boehringer Ingelheim Chemicals Closing Virginia API Manufacturing Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Boehringer Ingelheim Chemicals Closing Virginia API Manufacturing Facility



Boehringer Ingelheim Chemicals Inc. (BICI) will close its Petersburg, Virginia plant at the end of 2014. According to an Aug. 15, 2013 BICI press release, the facility will continue normal operations through the remainder of 2013 and phase out operations the following year. The closure will impact 240 employees through a multistage process starting in December 2013.

The Petersburg facility manufactures active ingredients for the pharmaceutical industry. BICI’s parent company, Boehringer Ingelheim, conducted a review of its current manufacturing capabilities worldwide, as well as needs in the industry, and determined that it had more capacity than the marketplace can sustain. BICI considered selling the facility but was unable to find a buyer. The company said it will begin working with its customers immediately to ensure a smooth transition to new suppliers.

Source: Boehringer Ingelheim Chemicals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here